In general, in patients with rheumatoid arthritis who have experienced primary failure to an anti-TNF-alpha drug, switching to a different therapeutic target (IL-6, CTLA-4, JAK) is postulated to be more effective than cycling to another anti-TNF-alfa [46,47,48,49]. The gene discussed is TNF; the disease is rheumatoid arthritis.